Tilray Brands (NASDAQ:TLRY) Trading Down 2.7% - Here's Why

Key Points

• Shares fell 2.7% intraday to as low as $6.65 on heavy volume (8.47M, +88% vs. average), and a director's sale of 33,556 shares has been flagged as a possible trigger for profit‑taking.
• Federal rescheduling toward Schedule III has boosted sector sentiment and Tilray's positioning for U.S. medical expansion, while large call‑option buying indicates speculative bullish positioning that can increase volatility.
• Near‑term risks include dilution worries from an at‑the‑market offering (up to ~$180M) and a "sell‑the‑news" pullback; analysts are mixed (consensus "Hold", average price target $11.50) and the company recently posted an EPS miss with deeply negative margins.

Tilray Brands, Inc. (NASDAQ:TLRY - Get Free Report) shares fell 2.7% during trading on Friday . The company traded as low as $6.65 and last traded at $6.75. 8,470,793 shares were traded during mid-day trading, an increase of 88% from the average session volume of 4,503,807 shares. The stock had previously closed at $6.94.

Key Tilray Brands News

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Federal rescheduling (Schedule I → III) materially improves the tax outlook for U.S. cannabis operators and has ignited a sector rally; while Tilray is more of a global/craft‑beverage play (so it's a sympathy beneficiary), the policy shift is broadly bullish for cannabis investor sentiment. Read More.
• Positive Sentiment: Tilray issued statements positioning the company to accelerate U.S. medical expansion and highlight its branded beverage and wellness channels, providing a narrative for upside if regulatory access materializes. Read More.
• Positive Sentiment: Large, unusual call‑option buying suggests speculative bullish positioning that can amplify intraday rallies (and volatility). Read More.
• Positive Sentiment: At least one Wall Street analyst (Roth Capital) is bullish and has given Tilray a sizable upside scenario, which supports momentum-driven buying. Read More.
• Neutral Sentiment: CEO interviews and media coverage reinforce the company’s strategic narrative around U.S. opportunity, but management has not yet provided concrete new U.S. revenue or timeline guidance. Read More.
• Neutral Sentiment: Trading experienced a LULD/volatility pause during the intraday surge — a market mechanism reflecting fast moves rather than changing fundamentals. (No single article; referenced in market coverage.)
• Negative Sentiment: Insider selling: a company director sold 33,556 shares (disclosed Form 4), which traders flagged and may have contributed to profit-taking. Read More.
• Negative Sentiment: “Sell‑the‑news” reversal and dilution concerns: early gains after the Schedule III headline faded as traders took profits, and an April prospectus for an at‑the‑market offering (up to ~$180M) resurfaced dilution worries—pressuring the stock. Read More.
• Negative Sentiment: Intraday coverage noted rapid fade after the premarket surge — the pattern (jump then giveback) underscores that today's move was driven more by policy headlines and momentum trading than by an immediate, company-level earnings or cash‑flow improvement for Tilray. Read More.

Analysts Set New Price Targets

A number of brokerages have recently commented on TLRY. ATB Cormark Capital Markets dropped their price target on Tilray Brands from $9.50 to $9.00 and set a "sector perform" rating on the stock in a research report on Thursday, April 2nd. Weiss Ratings reissued a "sell (d-)" rating on shares of Tilray Brands in a research report on Wednesday, January 21st. Wall Street Zen raised Tilray Brands from a "sell" rating to a "hold" rating in a research report on Saturday, March 21st. Roth Mkm raised Tilray Brands from a "neutral" rating to a "buy" rating and set a $10.00 price target on the stock in a research report on Thursday, April 2nd. Finally, TD Cowen lowered their price objective on Tilray Brands from $10.00 to $7.00 and set a "buy" rating on the stock in a research report on Monday, March 30th. Three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Tilray Brands has a consensus rating of "Hold" and an average price target of $11.50.

Tilray Brands Price Performance

The firm has a market capitalization of $786.71 million, a P/E ratio of -0.49 and a beta of 2.00. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.66 and a current ratio of 2.79. The firm has a 50-day moving average of $7.03 and a 200-day moving average of $9.51.

Tilray Brands (NASDAQ:TLRY - Get Free Report) last released its quarterly earnings data on Wednesday, April 1st. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.10). The business had revenue of $206.73 million during the quarter, compared to the consensus estimate of $201.35 million. Tilray Brands had a negative net margin of 156.51% and a negative return on equity of 3.31%. During the same period last year, the company posted ($0.87) earnings per share. As a group, analysts predict that Tilray Brands, Inc. will post -0.55 EPS for the current year.

Insider Transactions at Tilray Brands

In related news, Director David G. Hopkinson sold 33,556 shares of the company's stock in a transaction that occurred on Tuesday, April 21st. The stock was sold at an average price of $6.94, for a total value of $232,878.64. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 0.84% of the company's stock.

Institutional Investors Weigh In On Tilray Brands

Hedge funds have recently added to or reduced their stakes in the stock. Tudor Investment Corp ET AL purchased a new stake in Tilray Brands during the 3rd quarter valued at $518,000. Optiver Holding B.V. raised its stake in Tilray Brands by 239.4% during the 3rd quarter. Optiver Holding B.V. now owns 224,049 shares of the company's stock valued at $388,000 after buying an additional 158,041 shares during the last quarter. Cresset Asset Management LLC raised its stake in Tilray Brands by 72.1% during the 3rd quarter. Cresset Asset Management LLC now owns 501,989 shares of the company's stock valued at $868,000 after buying an additional 210,267 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its stake in Tilray Brands by 99,204,800.0% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 992,049 shares of the company's stock valued at $1,716,000 after buying an additional 992,048 shares during the last quarter. Finally, Zuckerman Investment Group LLC purchased a new stake in Tilray Brands during the 3rd quarter valued at $147,000. 9.35% of the stock is currently owned by hedge funds and other institutional investors.

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray's product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.